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TRANSFUSIONS IN THE UNITED STATES FROM
AN ADMINISTRATIVE MANAGED CARE
DATABASE
Grima D1, Marshall D1, Kleinman S2,AuBuchon J3, Kulin N1,
Cheng R4
1Innovus Research Inc, Burlington, ON, Canada; 2Kleinman
Biomedical Research,Victoria, BC, Canada; 3Dartmouth-
Hitchcock Medical Centre, Lebanon, NH, USA; 4 Protocare
Sciences Inc, Santa Monica, CA, USA
OBJECTIVE: Published data for the age distribution 
and survival of transfusion patients is either outdated
(Vamvakas, 1994) or non-US based (Mathoulin-Pellisier
2000; Tynell 2001). Vamvakas data were based on a
sample of patients transfused during surgery in Olmsted
county (MN) in 1981. The validity of such data for
current analyses is uncertain given changes in transfusion
practices. This study obtained current estimates of age at
transfusion and survival of transfused patients to popu-
late a cost-effectiveness model of screening volunteer
blood donations.
METHODS: Eligible patients had at least one code (ICD-
9-CM, CPT-4, HCPCS, UB-92) for blood transfusion in
1995 and were eligible for services one month surround-
ing the index transfusion date. Data were from a pro-
prietary managed care database containing private health
care claims and enrollment data representing health care
services provided through various managed care plans to
approximately 3 million members annually, including
Medicare-eligible individuals, in over 20 states. Age dis-
tribution and age-speciﬁc ﬁve-year survival of transfusion
recipients were calculated.
RESULTS: A total of 6,779 patients were included. The
baseline age distribution was: <16 years—4.7%, 16–45
years—14.4%, 46–65 years—21.3% and >65 years—
59.7%. This was similar to the distribution reported 
by Mathoulin-Pelissier, but with a larger proportion of
the population in the older age categories. Annual post-
transfusion mortality was estimated as: Year 1–31%,
Year 2–13%, Year 3–9%, Year 4–9%, and Year 5–8%
(percent of transfused cohort). These post-transfusion
mortality rates are about 5 percentage points greater than
those from the Vamvakas data. These data indicate that
morbidity of patients receiving transfusion in the US may
have risen since 1981; the new data may better represent
general practice across the US.
CONCLUSIONS: Current data conﬁrm that post-
transfusion mortality rates continue to be high, presum-
ably due to patient underlying disease, with over 40%
mortality within the ﬁrst two years of transfusion.
PHP16
PATIENT SATISFACTION AND
PHARMACEUTICAL OUTPATIENT CARE
Huttin CC
University of Paris, Paris, France and EIASM, Brussels, Belgium
OBJECTIVE: This research aims to build an information
system on pharmaceutical services, taking into account
patients’ opinions, to assess providers as well as health
care system performance and to provide a market 
surveillance tool, at a time where increasing hazards for
patients emerge from global trade and increased risks 
of counterfeiting and piracy. It also provides guidance 
on prescribing policies for clinical governance and 
policymakers.
METHODS: The patient survey combines patients’ opin-
ions and reported information about drug care, health
status and socio-demographic characteristics. Patients’
opinions are on information, clinical quality, access, com-
munication and trust. Reported information, to assess
system performance, is partly based on Prosper question-
naire from the Center for Quality of Care, HSPH (section
3). A sample of 251 patients was randomly selected, from
computerized patient registers of three practices in a 
UK Primary Care Group on three chronic conditions:
hypertension, asthma and diabetes.
RESULTS: Five rate-based patient satisfaction scores and
several reported scores on drug therapies for three chronic
conditions are presented. Large variations appear among
patient satisfaction scores, but mainly at practice level.
Highest opinion scores of practices are on communica-
tion and lowest scores on access. Around 13% of patient
think they receive confusing information and the rate is
especially high among asthmatic patients. Main sources
of confusion are between professionals and media infor-
mation sources. Reported information provides detailed
insight on areas and forms of confusion (side-effects, how
and when to take medications).
CONCLUSIONS: This paper shows that certain scores
may conﬂict with rational drug use policy and appropri-
ateness of uptake of medicines. Major problems in drug
supply and lack of business ethics challenge providers and
patients. Policy implications of such information system
on drug care will be discussed in order to address increas-
ing hazards for patient safety and pharmaceutical 
services.
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OBJECTIVE: Inappropriate prescribing can cause sig-
niﬁcant adverse events for all age groups. It is perhaps
most challenging and costly when it happens to vulner-
able population groups in general and the elderly in 
particular. Some studies explored the high prevalence and
demographic variables as risk factors of inappropriate
prescribing in the elderly. This study extends to examine
the impact of insurance type on inappropriate drug use
by the elderly.
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METHOD: Inappropriate geriatric medications were
deﬁned by well accepted explicit criteria. Logistic models
were employed to estimate the likelihood functions using
the 1996 Medical Expenditure Panel Survey (MEPS),
based on a national representative sample of the non-
institutionalized populations. Complex survey sample
design was adjusted in modeling.
RESULTS: When grouping all types of insurance together,
a dichotomous insurance variable captured no difference
in the likelihood of inappropriate medication use between
the insured and the uninsured groups. After distinguish-
ing the insurance type, it was found that the elderly 
with fee-for-service (FFS) coverage were more likely to 
use inappropriate prescriptions (OR = 1.73, 95% CI:
1.27–2.34), compared to those without coverage. This
effect was reduced but remained signiﬁcant after control-
ling for the total number of prescriptions (OR = 1.39,
95% CI: 1.01–1.90). In contrast, people with HMO type
of coverage were indifferent with the uninsured. More-
over, as expected, the most predictive variable of inap-
propriate prescriptions is the total number of medication
use, followed by worse health conditions and women.
CONCLUSION: When analyzing insurance impact on
drug utilization, distinguishing insurance type seemed to
be important. This study suggested a higher risk with FFS
model for inappropriate medication use compared to the
uninsured and others, the ﬁrst evidence of its kind based
on a national database. While this ﬁnding offers some
interesting implications for insurance policies, further
research is warranted to discern the reasons for the
observed adverse impact of FFS coverage.
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STOP: SMOKING CESSATION TARGET:
OBSERVATORY PROGRAM,THE FRENCH
PHYSICIAN’S PROGRESS
Taieb C, Myon E
PharmacoEconomics Programs, bioMérieux-Pierre Fabre,
Boulogne Billancourt, France
OBJECTIVE: The general practitioner is often the ﬁrst
professional involved in the treatment of tobacco depen-
dence, when he or she responds to the explicit request of
smokers to help end their tobacco consumption or asks
his or her patients about their situation in relation to
tobacco.
METHOD: The STOP programme, through a ques-
tionnaire distributed to around 6,000 doctors, aims to
describe the progress doctors are making with regard to
their own tobacco dependence as well as in the public
health initiative entrusted to them.
RESULTS: Here we present the preliminary results of this
investigation, through the analysis of the ﬁrst 300 ques-
tionnaires. The average age of our sample was 45 years;
75% were men. For 41% of the doctors that responded,
the setting up of a treatment programme takes place
during a speciﬁc consultation. The information supports
used come from the pharmaceutical industry (62%),
health insurance companies and anti-smoking associa-
tions (38%). 82% felt that the most relevant support was
patient information that they could distribute and that
would back up verbal advice. If 51% of doctors state that
they have never smoked, 62% of the smokers expressed
a desire to give up smoking, and 85% of them do not
consider their status as smokers as a hindrance to begin-
ning smoking cessation treatment with their patients.
Lack of training (3%), skepticism as to the effectiveness
of available treatments (4%), the absence of speciﬁc
remuneration (4%), do not seem to be the reasons for 
not beginning smoking cessation treatment with their
patients, unlike lack of time (49%) and patient resistance
(41%).
CONCLUSION: First professional involved, the general
practitioner should thus be recognised as a real partner
in Health policy and improve their commitment with it.
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MEDICATION SUPPORT PROGRAM IMPROVES
MEDICATION COMPLIANCE
Taitel MS, Frick J, Herman P, Kurcz L, Smith S
First Health, Downers Grove, IL, USA
Positive clinical outcomes are dependent on patients
adhering to their treatment plans. Improving patients’
medication compliance through a mail-based medication
support program that promotes preferred formulary
agents leads to improved clinical outcomes. It also results
in a win-win-win situation for patients, payers and indus-
try partners by increasing appropriate and cost-effective
utilization.
OBJECTIVES: This study assesses the effectiveness of 
a mail-based medication support program designed to
increase prescription reﬁll rates for selected maintenance
medications. All patients taking selected medications 
are sent a welcome package. Patients late in reﬁlling their
prescriptions are sent a reminder letter. Patients who do
not reﬁll are sent a second reminder letter. Patients 
who remain non-compliant may be called by a nurse case
manager. Patients who reﬁll a new prescription on a
timely basis are sent a congratulations letter.
METHODS: In phase one, reﬁll rates for patients receiv-
ing one or more reﬁll reminder letters are compared with
the reﬁll rates for a comparison sample of patients who
did not receive reminder letters. In phase two, to be com-
pleted Q1 2002, we will compare the reﬁll rates and cost
proﬁles between selected medications and a similar class
of unselected medications.
RESULTS: Phase one results show that patients who
received reminder letters proceeded to have 14,731 ﬁlls,
537,321 units for 431,200 days supply. This compares to
the control group, which had 10,329 ﬁlls, 376,736 units
for 302,331 days supply. The difference between the
groups shows that the intervention produced 4,403 ﬁlls,
160,585 units for 128,870 days supply.
CONCLUSIONS: Initial results show that a mail-based
medication reﬁll reminder program is an effective means
